ERBB2 and breast carcinoma: Besides that, in HER2-negative breast cancer patients who have residual invasive disease on pathological testing after a standard neoadjuvant chemotherapy containing anthracycline and taxane, the addition of adjuvant capecitabine therapy is also proven to prolong disease-free survival and overall survival (5).